Overview Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia Status: Completed Trial end date: 2016-01-01 Target enrollment: Participant gender: Summary The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as monotherapy in adults with schizophrenia. Phase: Phase 3 Details Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.